Replies to post #126021 on Biotech Values

[bladerunner1717]

re: IMMU

Can someone interpret this for me? Are these results good? Impressive?


IMMU $3.29 "Immunomedics reports Epratuzumab Phase IIB data demonstrating sensitivity of BICLA, a novel BILAG-based composite endpoint (IMMU) 3.29 : Co announces The results from the EMBLEM study demonstrated that the BICLA, whose components require clinical assessment, physician assessment, laboratory assessment, and recording of medication use, is a sensitive, clinically meaningful composite measure of SLE disease activity and may help to guide the design of future trials in SLE. In the EMBLEM study, the percentage of patients experiencing at least 1 serious adverse event was similar between the epratuzumab-treated group (7.0%) and placebo treated group (7.9%). Additionally, by Week 12, more patients in the epratuzumab 600mg weekly group, compared with placebo, had an improvement from BILAG A/B to BILAG D in the 6 body systems, indicating no active disease. A higher percentage of patients receiving epratuzumab 1200mg EOW, compared with placebo, had an improvement in baseline BILAG A/B scores to BILAG C or D in musculoskeletal, mucocutaneous, neuropsychiatric, and renal systems. In the cardiorespiratory system, all 7 patients in the epratuzumab 600mg weekly group had improved to a BILAG D at Week 12. Similarly, in the neuropsychiatric system, 5 out of 6 patients in the epratuzumab 600mg weekly group improved from BILAG B at baseline to BILAG D at Week 12. "


Bladerunner